• Guideline Summary
  • NGC:010722
  • 2015 Jun 2

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index.

  • Guideline Summary
  • NGC:009863
  • 2012 May 17

Risk reduction of prostate cancer with drugs or nutritional supplements.

  • Guideline Summary
  • NGC:010731
  • 2010 May (revised 2015 Jun)

Lower urinary tract symptoms in men: assessment and management.

  • Guideline Summary
  • NGC:010205
  • 2008 Feb (revised 2014 Jan)

Prostate cancer: diagnosis and treatment.

  • Guideline Summary
  • NGC:010496
  • 2014 Jul

Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.

  • Guideline Summary
  • NGC:009101
  • 1996 (revised 2012 Jul 17)

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

  • Guideline Summary
  • NGC:010457
  • 1995 (revised 2014)

ACR Appropriateness Criteria® lower urinary tract symptoms: suspicion of benign prostatic hyperplasia.

  • Guideline Summary
  • NGC:010182
  • 2013

ACR Appropriateness Criteria® high-dose-rate brachytherapy for prostate cancer.

  • Guideline Summary
  • NGC:010592
  • 1994 Jun (revised 2014 Nov 4)

Recommendations on screening for prostate cancer with the prostate-specific antigen test.

  • Guideline Summary
  • NGC:008543
  • 2011 Mar

Transrectal ultrasound guided biopsy of the prostate.

  • Guideline Summary
  • NGC:010893
  • 2016 Jan 27

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

  • Guideline Summary
  • NGC:010223
  • 2012 Oct 31

Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer.

  • Guideline Summary
  • NGC:008453
  • 1996 (revised 2011)

ACR Appropriateness Criteria® post-treatment follow-up of prostate cancer.

  • Guideline Summary
  • NGC:005951
  • 1995 (revised 2007 Jan; reaffirmed 2011)

Guideline for the management of clinically localized prostate cancer: 2007 update.

  • Guideline Summary
  • NGC:010892
  • 2016 Jan 27

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.

  • Guideline Summary
  • NGC:010181
  • 1996 (revised 2013)

ACR Appropriateness Criteria® definitive external-beam irradiation in stage T1 and T2 prostate cancer.

  • Guideline Summary
  • NGC:009671
  • 2005 (revised 2012)

ACR Appropriateness Criteria® prostate cancer—pretreatment detection, staging and surveillance.